Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2025 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizio
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to The Report
Fundraising

Arnatar Therapeutics

Arnatar Therapeutics Raises $52M in Series A

2022
Founded
45+
Employees
Cambridge, MA
Updated August 25, 2025
2 min read

Quick Facts

Arnatar Therapeutics Raises $52M in Series A


Arnatar Therapeutics has successfully raised $52M in a Series A led by Eight Roads and 3E Bioventures.


Company Overview


Arnatar Therapeutics is a HealthTech company headquartered in Cambridge, MA, founded in 2022 with 45+ employees.


Developing therapeutics for autoimmune and inflammatory diseases


Fundraising Details


  • Amount Raised: $52M
  • Round Type: Series A
  • Date: 2025-08-25
  • Investors: Eight Roads and 3E Bioventures

About Arnatar Therapeutics


Developing therapeutics for autoimmune and inflammatory diseases The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Cambridge, MA
  • Founded: 2022
  • Team Size: 45+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Arnatar Therapeutics's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Arnatar Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Looking Ahead


With this new capital, Arnatar Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-08-25. For more information about Arnatar Therapeutics, visit their headquarters at Cambridge, MA.

Topics

Fundraising(2912)HealthTech(503)Series AArnatar Therapeutics

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million